Carlton South Vic 3053, Australia
Go to Investors Hub
info@radiopharmtheranostics.com
Announcements

Radiopharm Theranostics
ASX Announcements

Stay fully informed with all investment-related announcements from Radiopharm Theranostics lodged with the ASX, including financial results, clinical trial updates, and corporate governance.

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Radiopharm Receives $4.5M R&D Tax Incentive
Quarterly Activities & Cash Report
Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for 161Tb-KLK3-mAb Phase I Clinical Trial in Australia
Notice Under Section 708A
Application for quotation of securities – RAD
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
Proposed issue of securities – RAD
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
Change of Director’s Interest Notice (IT)
Recent News

Cancer Research Milestones and 2025 Roadmap

Cancer Research Milestones and 2025 Roadmap Radiopharm Theranostics (ASX:RAD) is dedicated to developing innovative radiopharmaceutical products for both diagnostic and therapeutic applications, addressing high unmet medical needs. In 2024, the company made significant strides in its cancer research. In this

Categories
Analyst ReportsAnnouncementsAnnual ReportsInvestor PresentationsRAD ArticlesUpdates
Tags
Tags
Appendix 2A (1) Appendix 3B (1) Change of Director's Interest Notice (1) Cleansing Notice (1) PDF (33) Periodic Reports (25) Price Sensitive (84) Progress Report (2) Video (3) With Summary (2) With Video (4)
Archives
Archives
RSS RSS

Analyst Reports

RAD KOL Webinar on Pivalate
NDR and Webinar Takeaways Along with Upcoming Clinical Data
FQ4 Update: Modest Slippage in Some Readouts
Multiple Data Readouts on Track for 2H25
FY25 Appendix 4C and Business Update – Multiple Catalysts Approach in 2H25 Across Maturing Radioconjugate Pipeline
Radiopharm Theranostics (NASDAQ: RADX) Initiate with a Buy Rating and $18 Target Price
Our Most Important Update of the Year: FDA Removes “Invisible” Dose Ceiling for RLT, Opening a New Era of RLT Innovation; Reit. Buy on CATX, LNTH, RADX
PDL1 ADC Updates at ASCO25 Read Positively to RADXs PDL1T
Zachs Small-Cap Research RAD Initiating Coverage – Adding a Radio- isotope to Precision Oncology
Think Equity Update May 2025
Maxim Group Initiation of Coverage
Jones Research 3 Jan 2025 – Pre-JPM: Islands of Opportunities in a Sea of Uncertainty

Annual Reports

Annual Report Year Ended 30 June 2025
Annual Report
Annual Report to shareholders
Annual Report to shareholders

Investor Presentations

RAD Presentation August 2025
Close
Search

Hit enter to search or ESC to close

cookie By using this website, you agree to our cookie policy. Close